• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Oct. 27, 2011

View Archived Issues

Stock Movers

[[wysiwyg_imageupload:97:]] Read More

Other News To Note

• AtheroNova Inc., of Irvine, Calif., completed its pre-investigational new drug application meeting with the FDA for AHRO-001 in the prevention and regression of atherosclerotic plaque.• Emerald BioStructures, of Bainbridge Island, Wash., reported a three-year extension of its ongoing collaboration with Brussels, Belgium-based UCB SA, started in 2009, which will provide Emerald with research funding over the three-year period and the opportunity to receive milestones and royalties on future drug product revenues. Read More

Clinic Roundup

• Adventrx Pharmaceuticals Inc., of San Diego, said it reached an agreement with the FDA on a single pivotal trial for ANX-514 (docetaxel for injectable emulsion) in cancer. The 400-patient study will be a noninferiority design with a primary endpoint of comparing fluid retention following treatment with ANX-514 administered without corticosteroid premedication, vs. Taxotere (docetaxel) administered with corticosteroid premedication. ANX-514 is designed to improve the tolerability and safety of docetaxel and decrease toxicities. Read More

Pharma, Biotech, VCs Must Unite to Get Drugs to Market

PHILADELPHIA – With lengthy development cycles and the increasing costs of clinical work, well-established therapeutics sitting on pharmaceutical company shelves may be the lowest hanging fruit.The question is: Who is going to pay for them? Big pharmas are challenged to bring all of the promising products to market, despite budget constraints; biotechs are challenged to find funding for their own technologies; and venture capital firms are challenged to get returns on investments. Read More

Biopharma Seeks Sunlight On Disclosure Regulations

WASHINGTON – Still in the dark about how the government wants them to collect data about their payments to doctors beginning Jan. 1, 2012, drugmakers are seeking a little leniency and some swift clarity about what's expected of them under the Physicians Payment Sunshine provision.Since the Department of Health and Human Services (HHS) missed its Oct. Read More

Onyx, Bayer Enjoy 'Upside Surprise' on Regorafenib

Ahead of schedule, on Wednesday Onyx Pharmaceuticals Inc. and partner Bayer HealthCare Pharmaceuticals reported positive Phase III data for the VEGF-multikinase inhibitor regorafenib (BAY 73-4506) in patients with metastatic colorectal cancer (mCRC) whose disease has progressed after standard treatment.While keeping details under wraps, the companies said the trial met its primary endpoint of statistically significant improvement in overall survival. Read More

Panel: Focus on IP, Not Cash When Inking Multi-Asset Deals

SAN FRANCISCO – The final day of the 2011 BIO Investor Forum started with some encouraging news: The discovery-stage deal is alive and well for biotech.In the last two months alone, BioWorld Today has reported on several deals, including Ipsen SA's multi-asset deal with Syntaxin Ltd. for botulinum toxin drugs; Merck Serono SA's potential $691 million inflammatory disease antibody collaboration with F-Star GmbH; and Merck & Co. Inc. becoming the first major commercialization partner in an early stage deal for Zymeworks Inc.'s bi-specific antibody technology. Read More

Benlysta Sales, New Guidance Send HGSI Shares Down 22%

A trifecta of investor-unsettling news sent Human Genome Sciences Inc. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 5, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe